Liraglutide Safely Lowers Cardiovascular Risk By 13 Percent In Patients With Type 2 Diabetes After almost four years of clinical trials, a study on liraglutide has finally concluded. Results showed that the injectable drug can reduce cardiovascular risk by 13 percent in patients with type 2 diabetes, without any serious adverse effects. by Catherine Cabral-Isabedra
Health Eating At Least Four Servings Of Whole Grains Increases Life Span: Study by Catherine Cabral-Isabedra
Health Vaping Teens More Likely To Become Regular Cigarette Smokers: Study by Catherine Cabral-Isabedra
Science Australian Government Pledges $1 Billion To Preserve Great Barrier Reef by Catherine Cabral-Isabedra
Health High Levels Of Cobalt, Cadmium In Portland Detected Through Moss Study by Catherine Cabral-Isabedra
Health Successful Test For 3-Parent Babies Means Human Trials Might Begin By Late 2017 by Catherine Cabral-Isabedra